
Ongoing clinical trials
Curium ECLIPSE
diseaseName
This is a prospective, randomized, open-label, multicenter Phase 3 study evaluating the efficacy and safety of 177Lu-PSMA-I&T versus a switch in standard of care hormone therapy in men with metastatic
Sanofi IONA-MM OBS16577
Cancer
A prospective, non-interventional, multinational, observational study with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM)
EA5163
Cancer
EA5163-A Randomized, Phase III Study of Firstline Immunotherapy with or without Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC)
AstraZeneca D4194C00008
Cancer
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
Mirati 007
diseaseName
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Prostate cancer
EA8183
Prostate cancer
A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis
Head and neck cancer
Veru ARTEST V3002401
This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion.
Helsinn ANAM-17-20
Cancer
A phase 3, randomized, double-blind, placebocontrolled, multicenter study
Pfizer C4221016
diseaseName
A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab
Veru V2011801
diseaseName
To assess the safety and tolerability of sabizabulin monotherapy, and Trodelvy/sabizabulin combination therapy
Novocure LUNAR EF-24
Cancer
To test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while/on/after platinum based treatment
Breast cancer
BR007
Breast cancer
A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER
Veru ARTEST V3002401
This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion.
SpaceOar SABRE
diseaseName
To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.
Momenta MOM-M281-006
diseaseName
The primary objective is to evaluate the efficacy of M281 in patients with warm autoimmune hemolytic anemia (wAIHA).
Nektar Propel 20-214-36
diseaseName
This is a multicenter, randomized, open-label, Phase 2/3 study
Seattle Genetics SGNLVA-005
Cancer
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Natera 20-041-NCP
diseaseName
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Mirati 012
diseaseName
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Pancreatic cancer
A021602
Pancreas
RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)
Checkmate CMP-001-010
diseaseName
A multicenter, open-label, phase 2 study of intratumoral CMP-001 in combination withintravenous nivolumab in subjects with refractory unresectable or metastatic melanoma
Lilly JPCW
diseaseName
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study
Checkmate CMP-001-009
diseaseName
A multicenter, open-label, Phase 2 study of intratumoral CMP-001 in combination withntravenous PD-1–blocking antibody in subjects with selected types of advanced or metastatic cancer
S1929
Cancer
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib
BioAtla 3021
diseaseName
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
LIlly JZJX
diseaseName
LIBRETTO-432:A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in patients with Stage IB-IIIA RET fusion-Positive NSCLC
Prostate cancer
GU011
Prostate cancer
A PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC RADIOTHERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE CANCER (NRG PROMETHEAN)
Prostate cancer
GU010
Prostate cancer
PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)
Breast cancer
EA1183
Breast cancer
FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE
Breast cancer
BR004
Breast cancer
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Prostate cancer
GU002
Prostate cancer
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel
GU009
Cancer
Parallel phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurre
Lung cancer
CC003
Lung cancer
A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
S1802
Prostate cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Lung cancer
EA5181
Lung cancer
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable
BGB-3111-215
diseaseName
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrut
UTX-TGR-205-2b
diseaseName
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk
Bladder cancer
S1806
Bladder cancer
SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive
Lung cancer
S1914
Lung cancer
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
DCISionRT
diseaseName
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Prostate cancer
RTOG 3506
Prostate cancer
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with PostProstatectomy PSA Recurrences with Aggressive
BMS CA209-651
diseaseName
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of t
BMS CA209-234
Cancer
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
MROQC
Cancer
MROQC
TG Therapeutics 304
diseaseName
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic
UTX-TGR-205
diseaseName
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)